Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents

Why It Matters

Successful IPRs could strip Janssen of exclusivity on key golimumab indications, paving the way for biosimilar entry and revenue loss. The parallel BPCIA suit underscores growing regulatory and judicial scrutiny of biologic patent strategies.

Key Takeaways

• Four IPRs target Janssen's golimumab treatment patents
• Claims cover ankylosing spondylitis and psoriatic arthritis therapies
• Petitioners cite prior clinical trial data as anticipation
• Janssen faces BPCIA lawsuit alongside patent challenges
• Outcomes could affect market exclusivity for SIMPONI products

Pulse Analysis

The filing of four Inter Partes Review (IPR) petitions marks a decisive move by smaller biotech firms to challenge the patent shield surrounding Janssen's flagship anti‑TNF biologic, golimumab. By anchoring their arguments in publicly disclosed trial protocols and label information, the petitioners aim to demonstrate that the asserted method‑of‑treatment claims lack novelty or are obvious. This strategy reflects a broader trend where competitors leverage the PTAB process to erode the defensive moat of high‑value biologics, especially those protected by relatively recent patents that may not have withstood rigorous prior‑art scrutiny.

For Janssen, the stakes are substantial. Golimumab, marketed as SIMPONI® and SIMPONI ARIA®, generates significant U.S. sales, and any weakening of its patent portfolio could accelerate biosimilar entry. Biosimilar manufacturers monitor PTAB outcomes closely; a favorable ruling for the petitioners would likely trigger licensing negotiations or direct market competition, compressing margins for the originator. Moreover, the concurrent BPCIA infringement complaint amplifies the risk profile, as courts could issue injunctions that further limit Janssen's ability to enforce its patents while the IPRs are adjudicated.

The episode illustrates the increasingly aggressive posture of generic and biosimilar developers in the biologics arena. Companies are combining PTAB challenges with BPCIA litigation to create a multi‑front assault on patent exclusivity, forcing originators to reassess their IP strategies, invest in stronger patent drafting, and consider settlement pathways. Stakeholders—from investors to healthcare providers—should watch the PTAB rulings closely, as they will shape the competitive dynamics of the anti‑inflammatory biologic market and set precedents for future biologic patent disputes.